Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves' Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ Disease

key information

source: Clinical Endocrinology

year: 2016

authors: Aggarwal N, Tee SA, Saqib W, Fretwell T, Summerfield GP, Razvi S

summary/abstract:

Context:
Neutropenia secondary to antithyroid drug (ATD) therapy in Graves’ disease (GD) is well recognized. However, the effect of hyperthyroidism, prior to and after ATD therapy, on neutrophil counts in patients with GD is unclear.

Objective:
To study the prevalence of neutropenia in newly diagnosed untreated GD and the effect of ATD on the neutrophil count.

Design:
Prospective study from August 2010 to December 2014.

Setting:
Endocrinology outpatient clinic in a single centre.

Patients:
Consecutive patients (n = 206) with newly diagnosed GD.

Intervention:
ATD therapy.

Main Outcome Measures:
Prevalence and factors predicting neutropenia (<2 × 109 /l) and change in neutrophil counts following ATD.

Results:
At diagnosis, 29 (14•1%) of GD individuals had neutropenia. Non-Caucasians [odds ratio (95% CI) of 4•06 (1•14-14•45), P = 0•03] and patients with higher serum thyroid hormone levels [OR 1•07 (1•02-1•13), P = 0•002 for serum FT3] were the only independent predictors of neutropenia. All patients with neutropenia had normalized blood neutrophil levels after achieving euthyroidism with ATD therapy. In patients in whom data were available posteuthyroidism (n = 149), change in neutrophil count after achieving euthyroidism was independently related to reduction in thyroid hormone levels (P < 0•01).

Conclusions:
GD is associated with neutropenia in one in seven patients at diagnosis, especially in non-Caucasians and those with higher serum thyroid hormone levels. Neutrophil counts increase with treatment with ATD and are related to reduction in thyroid hormone concentrations. It is therefore important to check neutrophil levels in newly diagnosed patients with GD prior to commencing ATD therapy as otherwise low levels may incorrectly be attributed to ATD therapy.

organization: University Hospital of North Tees, UK; Gateshead Health NHS Foundation Trust, UK; Newcastle University, UK

DOI: 10.1111/cen.13133

Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close